+357 96 030922
info@marketpublishers.com

# Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others), By Region & Competition, 2020-2030F

https://marketpublishers.com/r/AF5539DF45A7EN.html
Date: March 2025
Pages: 187
Price: US$ 4,500.00 (Single User License)
ID: AF5539DF45A7EN

## Abstracts

Global Antibody Drug Conjugates Market was valued at USD 7.75 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.25% through 2030. The Antibody Drug Conjugates (ADCs) Market is a dynamic and rapidly evolving segment within the pharmaceutical and biotechnology industries. ADCs represent a groundbreaking class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. This synergy enables precise delivery of potent anticancer agents directly to cancer cells while sparing healthy tissue, thereby minimizing side effects associated with traditional chemotherapy. The market for ADCs has witnessed substantial growth driven by several key factors. Firstly, the increasing prevalence of cancer, both globally and across various cancer types, underscores the critical need for innovative and effective treatments. ADCs have emerged as a promising solution, offering improved therapeutic outcomes for patients with limited treatment options.

Key Market Drivers

Growing prevalence of cancer

The growing prevalence of cancer serves as a compelling driver for the Global Antibody Drug Conjugates (ADCs) Market. Cancer has reached alarming proportions worldwide,

with millions of new cases diagnosed annually. ADCs, a class of targeted cancer therapies, offer a ray of hope in the battle against this devastating disease. The rise in cancer cases underscores the unmet medical need for more effective and less toxic treatments. ADCs precisely deliver potent anticancer drugs to tumor cells, minimizing damage to healthy tissue, and hence are increasingly sought after. For instance, according to WHO, in 2022, an estimated 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally. By 2050, the cancer burden is expected to rise by 77%, placing greater pressure on health systems and communities. In the WHO Eastern Mediterranean Region, over 788,000 cancer cases were diagnosed in 2022. This number is projected to double to 1.57 million by 2045 due to population growth and widespread risk factors, including tobacco use, obesity, physical inactivity, unhealthy diets, and air pollution. Addressing these risks is crucial to mitigating the rising cancer burden in the region.

Key Market Challenges

Limited Tumor Types

Limited tumor types targeted by Antibody Drug Conjugates (ADCs) pose a significant challenge in the global market. ADCs are highly specific, and their effectiveness depends on the presence of specific antigens on cancer cells. This restricts their applicability to a select range of tumor types, leaving many cancers without effective ADC treatment options. Developing ADCs for a broader spectrum of tumors requires identifying suitable target antigens and investing in extensive research and development. Additionally, regulatory approval for new ADCs can be time-consuming and costly. Overcoming the limitation of tumor types is crucial to expand the market's reach and impact in the oncology field.

Key Market Trends

Growing pipeline of ADC candidates for various cancer indications.

The growing pipeline of Antibody Drug Conjugate (ADC) candidates for various cancer indications is a noteworthy trend in the global ADC market. This trend reflects the increasing interest and investment in ADC research and development, driven by several factors: The ADC field has witnessed a surge in research and investment, leading to the development of a diverse range of ADC candidates. These candidates target various cancer indications, including solid tumors and hematological malignancies. This expansion of the therapeutic landscape is a response to the unmet medical needs

across different cancer types. ADCs are known for their precision in targeting cancer cells while sparing healthy tissues. Advancements in genomics and biomarker discovery have enabled the identification of specific antigens and genetic profiles associated with different cancer types. This knowledge allows for the design of ADCs tailored to individual cancer subtypes, promoting personalized treatment approaches. The development of ADCs often goes hand in hand with research into combination therapies. Combining ADCs with other targeted therapies, immunotherapies, or standard chemotherapy regimens can enhance treatment efficacy. This trend aligns with the growing interest in combination approaches to address complex cancer biology. As cancer cells can develop resistance to single-agent therapies, researchers are exploring ADCs as a strategy to overcome resistance mechanisms. This has led to the development of ADCs that target specific resistance pathways or employ alternative mechanisms of action.

Key Market Players

Novartis AG

F. Hoffmann-La Roche Ltd

Takeda Pharmaceutical Company Limited

Pfizer Inc.

Seattle Genetics Inc

Genentech Inc

Immunogen Inc

Immunomedics Inc

Progenics Pharmaceuticals Inc

Bayer HealthCare Pharmaceuticals Inc

Report Scope:

+357 96 030922
info@marketpublishers.com

In this report, the Global Antibody Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antibody Drug Conjugates Market, By Type:

Monoclonal Antibodies

Linker

Drug/Toxin

Others

Antibody Drug Conjugates Market, By Application:

Blood Cancer

Breast Cancer

Ovarian Cancer

Lung Cancer

Brain Tumor

Others

Antibody Drug Conjugates Market, By Region:

North America

United States

Canada

Mexico

Europe

+357 96 030922
info@marketpublishers.com

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

+357 96 030922
info@marketpublishers.com

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Antibody Drug Conjugates Market.

Available Customizations:

Global Antibody Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

+357 96 030922
info@marketpublishers.com

# Contents

**1. PRODUCT OVERVIEW**

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

**2. RESEARCH METHODOLOGY**

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

**3. EXECUTIVE SUMMARY**

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

**4. VOICE OF CUSTOMER**

**5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET OUTLOOK**

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others)
  5.2.2. By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others)
  5.2.3. By Region

+357 96 030922
info@marketpublishers.com

5.2.4. By Company (2024)
5.3. Market Map

## 6. NORTH AMERICA ANTIBODY DRUG CONJUGATES MARKET OUTLOOK

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Types
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Antibody Drug Conjugates Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Types
6.3.1.2.2. By Application
6.3.2. Canada Antibody Drug Conjugates Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Types
6.3.2.2.2. By Application
6.3.3. Mexico Antibody Drug Conjugates Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Types
6.3.3.2.2. By Application

## 7. EUROPE ANTIBODY DRUG CONJUGATES MARKET OUTLOOK

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Types
7.2.2. By Application
7.2.3. By Country

7.3. Europe: Country Analysis
7.3.1. Germany Antibody Drug Conjugates Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Types
7.3.1.2.2. By Application
7.3.2. United Kingdom Antibody Drug Conjugates Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Types
7.3.2.2.2. By Application
7.3.3. Italy Antibody Drug Conjugates Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Types
7.3.3.2.2. By Application
7.3.4. France Antibody Drug Conjugates Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Types
7.3.4.2.2. By Application
7.3.5. Spain Antibody Drug Conjugates Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Types
7.3.5.2.2. By Application

**8. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES MARKET OUTLOOK**

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Types
8.2.2. By Application

8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Antibody Drug Conjugates Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Types
8.3.1.2.2. By Application
8.3.2. India Antibody Drug Conjugates Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Types
8.3.2.2.2. By Application
8.3.3. Japan Antibody Drug Conjugates Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Types
8.3.3.2.2. By Application
8.3.4. South Korea Antibody Drug Conjugates Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Types
8.3.4.2.2. By Application
8.3.5. Australia Antibody Drug Conjugates Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Types
8.3.5.2.2. By Application

**9. SOUTH AMERICA ANTIBODY DRUG CONJUGATES MARKET OUTLOOK**

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Types

9.2.2. By Application
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Antibody Drug Conjugates Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Types
9.3.1.2.2. By Application
9.3.2. Argentina Antibody Drug Conjugates Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Types
9.3.2.2.2. By Application
9.3.3. Colombia Antibody Drug Conjugates Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Types
9.3.3.2.2. By Application

## 10. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET OUTLOOK

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Types
10.2.2. By Application
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Antibody Drug Conjugates Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Types
10.3.1.2.2. By Application
10.3.2. Saudi Arabia Antibody Drug Conjugates Market Outlook

10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Types
10.3.2.2.2. By Application
10.3.3. UAE Antibody Drug Conjugates Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Types
10.3.3.2.2. By Application

**11. MARKET DYNAMICS**

11.1. Drivers
11.2. Challenges

**12. MARKET TRENDS & DEVELOPMENTS**

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisition

**13. GLOBAL ANTIBODY DRUG CONJUGATES MARKET: SWOT ANALYSIS**

**14. COMPETITIVE LANDSCAPE**

14.1. Novartis AG
14.1.1. Business Overview
14.1.2. Treatment Offerings
14.1.3. Recent Developments
14.1.4. Key Personnel
14.1.5. SWOT Analysis
14.2. F. Hoffmann-La Roche Ltd
14.3. Takeda Pharmaceutical Company Limited
14.4. Pfizer Inc.
14.5. Seattle Genetics Inc
14.6. Genentech Inc
14.7. Immunogen Inc

+357 96 030922
info@marketpublishers.com

14.8. Immunomedics Inc
14.9. Progenics Pharmaceuticals Inc
14.10.Bayer HealthCare Pharmaceuticals Inc

**15. STRATEGIC RECOMMENDATIONS**

**16. ABOUT US & DISCLAIMER**

+357 96 030922
info@marketpublishers.com

## I would like to order

Product name: Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Types (Monoclonal Antibodies, Linker, Drug/Toxin, Others), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others), By Region & Competition, 2020-2030F

Product link: https://marketpublishers.com/r/AF5539DF45A7EN.html

Price: US$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/AF5539DF45A7EN.html